When, in application of the second paragraph of Article L. 5124-11, the Director General of the Agence nationale de sécurité du médicament et des produits de santé intends to prohibit the export of a medicinal product, he shall first notify the pharmaceutical establishment carrying out the export of his intention and the reasons for it.
The latter has one month to submit its observations.
In urgent cases, the Director General of the Agency may immediately prohibit the export for a maximum period of six months.
Decisions to ban exports must state the reasons on which they are based. They are notified by the Director General of the Agency to the pharmaceutical establishment carrying out the export, which takes all necessary steps, in particular with other stockholders, to stop the export.
When the export of a medicinal product is prohibited pursuant to the third paragraph of Article L. 5124-11, the holder of the suspended or withdrawn marketing authorisation shall take all necessary steps to stop the export.